CSL AU000000CSL8

Report

Delayed Australian Stock Exchange - 05/25 10:09:07 pm EDT
271.35	AUD		-0.82%

05/23	Australian shares subdued as tech, healthcare offset mining gains	RE
05/11	Australia shares slide as U.S. inflation data fuels slowdown woes	RE
05/11	Australian shares rise on healthcare, mining boost; U.S. inflation data in focus	RE

News

Press Releases

Official Publications

Sector news

MarketScreener Strategies

Communiqués de presse de la société CSL LIMITED

03/29	CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat..	AQ
03/28	Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Q..	AQ
03/23	CSL BEHRING AG - PUBLICATION OF PROV : Participation rate of 94 percent	AQ
03/08	PUBLICATION OF DEFINITIVE INTERIM RE : CSL Behring AG declares offer successful	BU
03/07	Seqirus - Update on CDC Advisory Committee on Immunization Practices (ACIP) Review of E..	AQ
03/06	CSL : Notification regarding unquoted securities - CSL	PU
03/03	CSL : Notification regarding unquoted securities - CSL	PU
03/03	Vifor Pharma Group - Publication of provisional interim result for Vifor Pharma tender ..	AQ
03/03	Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022	AQ
02/23	CSL : Change of Director's Interest Notice	PU
02/23	CSL : Notification regarding unquoted securities - CSL	PU
02/15	CSL : Half Year Results Investor Presentation	PU
02/15	CSL : Half Year Results Announcement	PU
02/15	CSL : Statutory Accounts for Half Year Ended 31 December 2021	PU
02/13	CSL : Application for quotation of securities - CSL	PU
02/07	CSL Behring - Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained..	AQ
01/06	CSL : Notification regarding unquoted securities - CSL	PU
2021	Global biotherapeutics - CSL Behring Receives Accelerated CHMP Assessment for Etranacog..	AQ
2021	CSL : Investor Presentation CSL Swiss Tender Acquisition of Vifor	PU
2021	CSL : Proposed issue of securities - CSL	PU
2021	CSL : Swiss tender offer to acquire 100% of vifor pharma ltd	PU
2021	CSL : Committed to mRNA Program	PU
2021	CSL : Statement on Modern Slavery 2021	PU
2021	CSL : Tax Transparency Report 2021	PU
2021	CSL : Joins StartX Community	PU
2021	CSL : Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and N..	AQ
2021	CSL : The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based ..	AQ
2021	CSL : Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines	AQ
2021	CSL : Launches Annual Scholarship Program with Seven Greater Chicago Area Students Receivi..	AQ
2021	CSL : Positive COVID-19 Case at Broadmeadows	PU
2021	CSL : Annual Report	PU
2021	CSL : Uncertainty Prevails For CSL	AQ
2021	CSL : Results Announcement	PU
2021	CSL : Dividend/Distribution - CSL	PU
2021	CSL : Results Presentation	PU
2021	CSL : Statutory Accounts for the Full Year Ended 30 June 2021	PU
2021	CSL : The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Forc..	AQ
2021	CSL : Hizentra (Immune Globulin Subcutaneous 20% Liquid) To Be Covered Under Medicare Part..	AQ
2021	CSL : Applications Open for Fellowships	PU
2021	CSL : California Adds New Residential Remodeling Contractor License Classification, Effect..	AQ
2021	CSL : welcomes the Patent Box Policy	PU
2021	CSL : welcomes domestic mRNA vaccine development	PU
2021	UNIQURE N : CSL Behring Announces Closing of Global Commercialization and License Agreemen..	AQ
2021	CSL : Behring Announces Agreement with uniQure	PU
2021	CSL : Update on COVID-19 Vaccine Numbers	PU
2021	CSL : 2020 RAI Awardees Announced	PU
2021	CALIFORNIA CONTRACTORS : New CSLB Procedure Requires Non-California Corporations To Associ..	AQ
2021	CSL : update on ATAGI advice for AZ COVID-19 Vaccine	PU
2021	CSL : Global Role in Battling COVID-19	AQ
2021	CSL : Global Role in Battling COVID-19	PU
2021	CSL : COVID-19 Update	PU
2021	CSL : Dispatches COVID 19 Vaccine	PU
2021	CSL : Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans	AQ
2021	CSL : Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Base..	AQ
2021	CSL : Is CSL Ready To Turn Around?	AQ
2021	CSL : COVID-19 Update	PU
2021	CSL : Local Manufacturing of COVID-19 Vaccine Update	PU
2021	CSL : Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engage..	AQ
2020	CSL : COVID-19 Update	PU
2020	CSL : Update on the UQ COVID-19 vaccine	PU
2020	CSL : Global Role in Battling COVID-19	PU
2020	CSL : COVID-19 Update	PU
2020	CSL : Update on UQ-CSL v451 COVID-19 Vaccine	PU
2020	CSL : Urban League, CSL Behring Partner to Address Community Needs including Public Health..	AQ
2020	CSL : New Vaccine Manufacturing Facility	PU
2020	CSL : Behring to Present New Real-World Data on Outcomes Following Acute Coronary Syndrome..	AQ
2020	CSL : Appendix 2A	PU
2020	CSL : University of Oxford/AstraZeneca Vaccine Candidate	PU
2020	CSL : Named as one of the World's Best Employers	AQ
2020	CSL : Broad Response to COVID-19 and Advancements across the Company's Strategic Scientifi..	AQ
2020	CSL : Annual Research and Development Day Briefing	PU
2020	CSL : Agreement to supply 51 mil vaccine doses	PU
2020	CSL : Notice of Research & Development Investor Briefing	PU
2020	CSL : Appendix 3G	PU
2020	CSL : Change of Director's Interest Notice	PU

1 2 3 4 Next

Analysis

KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health